论文部分内容阅读
癌胚抗原(Carcinoembryonic Antigen, C E A)自1965年Gold首先应用以后,开辟了“肿瘤标志物”(Tumor Marker)研究的新里程.20多年来,各家对其应用价值褒贬不一,评价相差甚大.主要问题是特异性较差,除肠、胃道肿瘤外,许多良性疾患如直肠息肉,溃疡性结肠炎,胆囊炎,酒精性肝硬化,肺纤维化,肺气肿,肺结核,肺炎,糖尿病,高血压等都有一定的阳性率,健康人的吸烟也有影响.健康人,肿瘤与非肿瘤性疾患的血清CEA浓度综合如表一.然而,CEA仍与多种肿瘤,尤其是肠道肿瘤密切相关.这种关系的密切程度可分四级:一级是胚胎时期产生CEA的组织—结肠;二级是由胚胎期相同的细胞系—胃肠内
Carcinoembryonic Antigen (CEA) has been used since Gold’s first application in 1965. It has opened up a new era of Tumor Marker research. For more than 20 years, various applications have been evaluated in various ways. There is a big difference. The main problem is that the specificity is poor. In addition to intestinal and gastric tumors, many benign diseases such as rectal polyps, ulcerative colitis, cholecystitis, alcoholic liver cirrhosis, pulmonary fibrosis, emphysema, tuberculosis, pneumonia There are certain positive rates for diabetes, hypertension, etc. Smoking in healthy people also has an effect. The serum CEA concentrations in healthy individuals, tumors and non-neoplastic diseases are summarized in Table 1. However, CEA is still associated with a variety of tumors, especially the intestines. Tumors are closely related. The closeness of this relationship can be divided into four levels: the first stage is the tissue that produces the CEA in the embryonic stage - the colon; the second stage is the same cell line in the embryonic stage - the intestine